Market Currents
Amarin (AMRN) announces $100M in non-equity financing with an investment fund managed by...
-
Thursday, December 6, 2012, 4:21 PM ETAmarin (AMRN) announces $100M in non-equity financing with an investment fund managed by Pharmakon Advisors, and that it's continuing preparations to commercialize Vascepa capsules by hiring a sales force in the United States. Payments under this hybrid debt-like instrument are expected to be made over a 3.5-year period commencing in November 2013 and to continue through early 2017. Shares -21% AH.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 16 comments:
I know this is cheap, but as the market keeps on proving, it can always get cheaper. I won't add any more shares above $8.
Use your brain, do some research and come back and explain how amrn drug is way superior compared to lovaza. Please don't make these kind of stupid statements without even knowing how these two therapies differ in terms of safety profile and efficacy.
The only main difference between Vascepa and Lovaza is that Vascepa does not raise LDL-C. Most patients with high triglycerides would already be on a statin therapy anyways. The clinical efficacy of lowering of triglycerides is comparable to one another.
Ever wonder why Vascepa hasn't done a head to head with Lovaza? I'm guessing it's because they don't see it being any more superior in triglyceride lowering.
Omegawatcher has no more than 7 comments, all of them raising doubts on Amarin's Vascepa. I wouldn't be surprised if this account belonged to Adam Feuerstein, the Criminal, or to any of his minions.
Who exactly is Adam Feuerstein? http://bit.ly/zcz1QE
After so much senseless defamation ... why is he not behind bars!? After all, that's where criminals belong: in jail.